Drug discovery companies identify, validate and develop new therapeutic candidates for the prevention and treatment of disease. The sector combines biology, chemistry, data science and clinical expertise to bring new medicines from concept to clinic.
This category includes companies working on:
Browse 422 UK drug discovery companies below.
Global population genomics platform for drug target discovery and clinical trials
Omnigen Biodata is a biotechnology company operating the Discover Me platform, a global population health and genomics research programme integrating health and genetic data from…
Biparatopic PD-1/VEGFR2 antibody for solid tumour oncology
Ottimo Pharma is a clinical-stage biotechnology company developing biparatopic antibody therapeutics for solid tumour cancers. Its lead programme, Jankistomig, is a first-in-class…
Therapeutic antibodies targeting the angiotensin AT1R pathway in cancer
aTen Therapeutics is a Scottish pre-clinical biotechnology company developing therapeutic monoclonal antibodies against the angiotensin-II type I receptor (AT1R), which is…
Non-invasive small molecule eye drops for retinal vascular disease
Foventa is a biopharmaceutical company developing non-invasive, small molecule therapeutics for retinal vascular diseases that can cause vision loss. Its lead candidate targets…
Epigenetic reprogramming and senolytic therapeutics for cancer and ageing
199 Biotechnologies is a preclinical-stage biotechnology company developing epigenetic reprogramming and senolytic therapies targeting cancer and age-related disease. Its lead…
Rare disease partnering platform connecting patient groups with drug developers
Aspire Biosciences is a Cambridge-based company accelerating treatment development for rare and unaddressed diseases through its Systematic Serendipity methodology. The company…
Ultra-high-throughput biologics discovery platform powered by generative AI
Sortera Bio is a biotechnology company developing an AI-powered platform for the discovery and engineering of biological therapeutics. The Deep Screening platform generates…
Immunotherapies targeting blood cancer precursor conditions before onset
Athernal Bio is a Cambridge-based biotechnology company developing targeted immunotherapies for high-risk clonal haematopoiesis, a widespread blood stem cell mutation condition…
AI and multi-omics platform for cardiovascular drug target discovery
CardiaTec Biosciences is a Cambridge-based biotech applying artificial intelligence to large-scale multi-omic data to identify novel drug targets for cardiovascular diseases. Its…
Clinical-stage therapeutics for oncology and behavioural brain disorders
TheraCryf is a clinical-stage drug development company developing small-molecule therapeutics for oncology and behavioural brain disorders. Its lead oncology candidate, derived…
Specialty pharma delivering niche medicines and novel drug delivery technology
Therakind is a specialty pharmaceutical company focused on developing niche medicines for difficult-to-treat patient populations, including children and the elderly. The company…
Cardioprotective protein therapeutics for acute heart attack treatment
Forcefield Therapeutics is a biotechnology company developing protein-based therapeutics to protect heart muscle following acute myocardial infarction. The company's approach uses…